Vorinostat MSD vorinostat regulatory update

Merck withdrew an MAA for Vorinostat MSD vorinostat to treat advanced refractory cutaneous T cell lymphoma (CTCL). The company said it withdrew the application based on the view of the EMEA's CHMP tha...